Charles Winslow Completes Annual Internal Strategic Review at Lumena Intelligent Alliance Office
Jersey City, NJ, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Lumena Intelligent Alliance…
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
December 18, 2025 19:00 ET | Source: Mesa Laboratories, Inc. LAKEWOOD, Colo.,…
Xinhua Silk Road: Annual wine-themed folk culture festival held in E. China’s Jiangxi Province
BEIJING, Dec. 17, 2025 /PRNewswire/ -- A wine-themed folk culture festival kicked off…
GEDU Global Education Signs Agreement with United Nations Agency UNITAR during XXII CIFAL Annual Meeting in London
LONDON, Dec. 17, 2025 /PRNewswire/ -- UK-based education multinational GEDU Global Education has…
12TH ANNUAL WINTERNATIONAL EMBASSY SHOWCASE DRAWS 8,000 GUESTS
70 Embassies Unite to Celebrate Global Culture and Traditions at the Ronald…
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
December 11, 2025 18:22 ET | Source: Mesoblast Limited NEW YORK, Dec.…
Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc.…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear…
